Ocugen gains as COVID-19 vaccine booster effective against Omicron, Delta in study

Hanall Biopharma

12/01/2022 13:18

** Shares of biopharma co  OCGN.O  rise 4% to $4.34
premarket
    ** Booster dose of company's COVID-19 vaccine candidate,
Covaxin, generates robust neutralizing antibody responses
against both Omicron and Delta variants, according to results
from a study conducted at Emory University  urn:newsml:reuters.com:*:nGNX5GCdp3
    ** More than 90% of all individuals boosted with Covaxin six
months after the primary series showed neutralizing antibodies
against Omicron, says OCGN, adding that the shot's effectiveness
was comparable to that of mRNA-based vaccine boosters 
    ** Covaxin was developed by Bharat Biotech and OCGN is
co-developing it for the U.S. and Canadian markets
    ** The vaccine has been approved for emergency use by the
World Health Organization and  is currently under review by the
U.S. FDA for emergency use authorization for children between 2
and 18 years
    ** In November, U.S. FDA issued clinical hold on OCGN's
application seeking clearance to begin clinical trial of Covaxin
in adults  urn:newsml:reuters.com:*:nL4N2SH2ZC
    ** Stock down 8.6% YTD up to the last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))